A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment
Sponsored by Takeda
About this trial
Last updated 7 months ago
Study ID
TAK-279-3001
Status
Active, not recruiting
Type
Interventional
Phase
Phase 3
Placebo
Yes
Accepting
18+ Years
All
Not accepting
Healthy Volunteers
Trial Timing
Started 2 years ago
What is this trial about?
The main aim of this study is to show how well TAK-279 reduces the skin plaques compared
to placebo, in participants with moderate-to-severe plaque psoriasis. Participants will
be assigned to one of the 3 study treatments (TAK-279, apremilast (an approved
treatment), or a placebo). Participants will be in the study for up to 61 weeks.
What are the participation requirements?
Inclusion Criteria
Must be men and women of 18 years and older.
Must have a diagnosis of moderate-to-severe plaque psoriasis which hasn’t changed for at least 6 months.
Must be a candidate for light therapy (phototherapy) or therapy that treats the whole body (systemic therapy).
Exclusion Criteria
Cannot have a type of psoriasis that is not plaque psoriasis
Cannot have previously taken TAK-279, deucravacitinib (a similar medicine), or apremilast
Cannot have had a recent infection or have a history of certain infections